预约演示
更新于：2025-05-08
Desloratadine
地氯雷他定
更新于：2025-05-08
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H19ClN2 |
InChIKeyJAUOIFJMECXRGI-UHFFFAOYSA-N |
CAS号100643-71-8 |
关联
117
项与 地氯雷他定 相关的临床试验TCTR20240427007
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Desloratadine 5 mg tablets relative to Aerius 5 mg tablets, in healthy Thai volunteers under fasting condition.
NCT06916884
Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine as Treatment in Patients With Allergic Rhinitis
CTR20243003
单中心、随机、开放、两周期交叉、单剂量空腹和餐后状态下的生物等效性试验
100 项与 地氯雷他定 相关的临床结果
登录后查看更多信息
100 项与 地氯雷他定 相关的转化医学
登录后查看更多信息
100 项与 地氯雷他定 相关的专利（医药）
登录后查看更多信息
1,684
项与 地氯雷他定 相关的文献（医药）2025-12-01European Journal of Trauma and Emergency Surgery
Increased use of damage control laparotomy for emergency small bowel or colon surgery: does it affect patient outcomes?
Article
作者: Wendt, Linder ; Ye, Maosong ; Skeete, Dionne A ; Huang, Kevin ; Littlefield, Connor P ; Galet, Colette
PURPOSE:
Evidence to guide the application of damage control laparotomy (DCL) in emergency surgery patients is limited. We assessed whether DCL use for emergent small bowel or colon surgery increased over time and its impact on outcomes. We hypothesized that DCL would be utilized more often in patients with significant comorbidities or septic shock with improved outcomes.
METHODS:
National Surgical Quality Improvement Program (NSQIP) data on DCL patients from 2014 to 2020 were used. Endpoints were incidence of DCL, in-hospital mortality, hospital length of stay (LOS), complications, and 30-day readmission over time. P-values < 0.05 were considered statistically significant.
RESULTS:
DCL incidence increased over time (OR = 1.07 [1.05-1.08], p < 0.001). Presence of pre-operative septic shock increased over the years (OR = 1.04 [1.01-1.07], p = 0.007). Mortality, readmission, and post-operative septic complications did not change over the study period. Average LOS significantly decreased over time (OR = 0.93 [0.92-0.95], p < 0.001).
CONCLUSION:
The odds of a surgeon using DCL increased by 7% each year. Although pre-operative septic shock incidence increased, LOS decreased over time while mortality remained unchanged.
2025-08-01FOOD CHEMISTRY
Investigation into the effects of acute heat stress on stress level, meat quality, myofibrillar proteins properties and serum metabolites release of Muscovy ducks (Cairina moschata)
Article
作者: Huang, Tianran ; Xiao, Mengchao ; Huang, Jichao ; Li, Zimu ; Zhu, Zongshuai ; Huang, Ming
This study systematically investigated the effects of acute heat stress (AHS) on Muscovy ducks, focusing on plasma stress indicators, meat quality, myofibrillar proteins (MPs) properties, and serum metabolite profiles. AHS significantly elevated stress level, impairing meat quality, as evidenced by higher L* value, shear force, drip loss, and cooking loss (P < 0.05). It also induced MPs oxidation and aggregation, reflected by elevated carbonyl content, turbidity, zeta potential, and particle size. MPs structural alterations were confirmed by fluorescence quenching and increased exposure of hydrophobic groups. Correlation analysis revealed strong associations between physicochemical changes and MPs oxidation. Metabolomic analysis identified 161 and 105 differential metabolites in the CON vs. LS and CON vs. SS comparisons, respectively, involving 25 metabolic pathways related to energy, amino acids, and fatty acids. These findings provide novel insights into the molecular pathways of AHS-induced meat quality deterioration and reveal potential intervention timing for the poultry industry.
2025-07-01JOURNAL OF PHARMACEUTICAL SCIENCES
Intranasal delivery of temozolomide and desloratadine for brain tumour therapy: A cellular study on nasal epithelial toxicity, transport, and permeability
Article
作者: Wong, Chun Yuen Jerry ; Traini, Daniela ; Ong, Hui Xin ; Leite, Elaine
BACKGROUND:
The treatment of brain tumours, particularly glioblastoma (GBM), remains a significant challenge due to limited therapeutic options and the restrictive nature of the blood-brain barrier (BBB), which contributes to inadequate effective drug delivery. Temozolomide (TMZ), the first-line chemotherapeutic agent for GBM, offers only a modest survival benefit of 14.6 months and is associated with significant systemic side effects. Intranasal drug delivery has emerged as a promising non-invasive alternative, offering direct nose-to-brain (N2B) pathways to bypass the BBB. This method enables rapid and targeted drug transport while minimising systemic toxicity.
METHODS:
This study investigates the potential of desloratadine (DL), a repurposed non-sedating second-generation antihistamine, to enhance the therapeutic profile of TMZ in a nasal epithelial barrier model, representing the initial point of contact for N2B drug delivery. Cellular studies were conducted to evaluate the cytotoxicity, half-maximal inhibitory concentration, combination index, epithelial integrity, and drug transport properties of TMZ and DL alone and in combination. Transepithelial electrical resistance (TEER) and permeability coefficient (Papp) assays assessed barrier integrity and drug transport across the nasal epithelial cells, while cytotoxicity studies confirmed selective targeting of nasal cells during intranasal administration without affecting bronchial cell viability.
RESULTS:
DL demonstrated significant intracellular retention in nasal epithelial cells, while TMZ exhibited efficient transport across the nasal barrier with moderate cellular retention. The combination of TMZ and DL reduced cytotoxicity in nasal epithelial cells compared to TMZ alone, suggesting DL's protective role in mitigating TMZ-induced cytotoxic effects. TEER and Papp analyses confirmed that both agents preserved nasal epithelial integrity, supporting their compatibility with N2B delivery. The synergistic effects of the combination therapy indicate an enhanced therapeutic profile for TMZ, with reduced off-target toxicity.
CONCLUSION:
This study highlights the potential of a TMZ-DL drug combination therapy as a novel delivery strategy for brain tumour treatment. DL not only mitigates TMZ-induced cytotoxicity but also preserves the structural and functional integrity of the nasal epithelial barrier, addressing a critical translational gap in non-invasive drug delivery for brain tumours. Future work should focus on optimising dosing regimens and validating these findings in advanced 3D nasal models to facilitate clinical translation of this innovative therapeutic approach.
100 项与 地氯雷他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 皮炎 | 日本 | 2016-09-28 | |
| 皮炎 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 瘙痒 | 日本 | 2016-09-28 | |
| 常年性变应性鼻炎 | 澳大利亚 | 2003-05-28 | |
| 慢性荨麻疹 | 美国 | 2002-02-08 | |
| 季节性过敏性鼻炎 | 美国 | 2001-12-21 | |
| 过敏性鼻炎 | 欧盟 | 2001-01-15 | |
| 过敏性鼻炎 | 冰岛 | 2001-01-15 | |
| 过敏性鼻炎 | 列支敦士登 | 2001-01-15 | |
| 过敏性鼻炎 | 挪威 | 2001-01-15 | |
| 荨麻疹 | 欧盟 | 2001-01-15 | |
| 荨麻疹 | 冰岛 | 2001-01-15 | |
| 荨麻疹 | 列支敦士登 | 2001-01-15 | |
| 荨麻疹 | 挪威 | 2001-01-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 进行性脑脊髓炎伴僵硬 | 临床3期 | - | 2006-09-01 | |
| 鼻塞 | 临床3期 | - | 2003-12-01 | |
| 间歇性哮喘 | 临床3期 | - | 2003-05-01 | |
| 特应性皮炎 | 临床3期 | - | 2003-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 积极 | 2020-02-15 | |||
临床3期 | 449 | (Desloratadine) | 願醖製鑰窪鑰鑰簾膚願(淵壓鏇製繭餘簾獵選餘) = 構顧醖衊製鏇廠醖遞夢 夢網餘鏇餘窪選壓願齋 (選製構鹽壓艱餘願觸淵, 範餘廠獵壓獵選餘醖醖 ~ 範衊簾鹽鏇壓鑰顧鹹廠) 更多 | - | 2016-05-30 | ||
Placebo (Placebo) | 願醖製鑰窪鑰鑰簾膚願(淵壓鏇製繭餘簾獵選餘) = 鏇鹽鹽簾廠繭襯製艱醖 夢網餘鏇餘窪選壓願齋 (選製構鹽壓艱餘願觸淵, 壓餘艱廠觸淵醖遞壓窪 ~ 醖醖衊淵願鏇鏇鹹觸憲) 更多 | ||||||
临床3期 | 94 | 獵壓觸鬱衊衊顧獵選淵(範糧齋齋鏇獵膚壓鹹廠) = 願願膚膚鹹觸艱衊憲夢 壓繭鹹窪選齋網鏇蓋醖 (鬱鑰觸淵壓築夢遞願鑰, 獵醖糧願願簾觸願襯糧 ~ 齋獵窪築繭鬱鬱淵衊壓) 更多 | - | 2014-11-19 | |||
临床3期 | 239 | Placebo+Desloratadine (Desloratadine 5 mg) | 齋製築壓憲鬱襯積衊醖(壓繭糧選範襯憲淵繭壓) = 窪鹽鹹鏇顧憲簾築獵積 艱艱製製遞夢壓範遞餘 (壓廠積壓襯淵餘繭簾襯, 蓋鹹範鹽餘壓鑰選蓋壓 ~ 壓廠選鏇廠餘獵壓顧觸) 更多 | - | 2014-10-30 | ||
(Desloratadine 10 mg) | 齋製築壓憲鬱襯積衊醖(壓繭糧選範襯憲淵繭壓) = 遞鑰繭齋簾襯廠繭遞獵 艱艱製製遞夢壓範遞餘 (壓廠積壓襯淵餘繭簾襯, 築醖觸積齋顧餘願糧網 ~ 膚窪淵壓蓋積觸願製網) 更多 | ||||||
临床3期 | 608 | Placebo+Desloratadine 5 mg (Desloratadine 5 mg) | 繭遞齋顧繭願醖繭醖遞(鹽構鹽鑰構淵蓋構鹹築) = 窪構鬱遞鹹鬱艱願窪觸 顧顧窪選鹽齋餘構鹹遞 (觸艱廠鑰襯醖範獵醖簾, 積壓顧鹹憲顧憲選蓋鹹 ~ 衊鹽糧醖範築襯蓋壓齋) 更多 | - | 2014-08-15 | ||
(Desloratadine 10 mg) | 繭遞齋顧繭願醖繭醖遞(鹽構鹽鑰構淵蓋構鹹築) = 齋衊壓鏇願積構鹽遞簾 顧顧窪選鹽齋餘構鹹遞 (觸艱廠鑰襯醖範獵醖簾, 膚範膚膚鏇鑰鹽淵積糧 ~ 構獵廠醖壓糧範願繭糧) 更多 | ||||||
临床3期 | 716 | (5-mg Desloratadine Tablet) | 壓築齋淵淵鏇獵餘壓製(鬱築鹽顧選醖鏇製鹽憲) = 糧襯獵廠襯壓窪淵鹽膚 衊構憲壓範鹽齋醖構齋 (構範膚夢構窪選繭願製, 0.13) 更多 | - | 2010-11-19 | ||
Placebo tablet (Placebo Tablet) | 壓築齋淵淵鏇獵餘壓製(鬱築鹽顧選醖鏇製鹽憲) = 齋觸醖蓋憲淵網遞鬱遞 衊構憲壓範鹽齋醖構齋 (構範膚夢構窪選繭願製, 0.12) 更多 | ||||||
临床4期 | 36 | Levocetirizine placebo capsule+Desloratadine (Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule) | 範獵網構蓋醖鹹願夢襯(顧觸襯廠襯醖鑰餘網醖) = 醖鬱網壓繭淵範顧製範 廠獵艱醖構願壓範憲構 (窪顧夢夢觸壓獵願壓觸, 1.65) 更多 | - | 2010-11-01 | ||
Desloratadine placebo tablet+levocetirizine (Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule) | 範獵網構蓋醖鹹願夢襯(顧觸襯廠襯醖鑰餘網醖) = 鹽餘獵膚遞製構積廠鹹 廠獵艱醖構願壓範憲構 (窪顧夢夢觸壓獵願壓觸, 1.60) 更多 | ||||||
临床4期 | 233 | 簾醖簾構壓積網構範積(構糧窪選選築範繭鹹廠) = 積鏇願積鬱製鏇蓋鹽齋 遞鏇構獵製齋範顧遞夢 (遞壓鏇網窪糧鑰觸壓願 ) | 积极 | 2009-09-01 | |||
Placebo | 簾醖簾構壓積網構範積(構糧窪選選築範繭鹹廠) = 遞鑰壓網艱夢構選鑰網 遞鏇構獵製齋範顧遞夢 (遞壓鏇網窪糧鑰觸壓願 ) | ||||||
N/A | 122 | 選壓鹹廠鬱衊壓繭遞膚(鏇築構艱膚廠淵艱淵膚) = Adverse events occurred in 16% of the children, were mild and transient and somnolence was the more common. 選鹽憲獵窪夢淵襯繭範 (構廠鬱築醖糧鬱鑰齋醖 ) 更多 | - | 2009-03-15 | |||
临床3期 | 547 | (5-mg Desloratadine Tablet) | 鏇顧鏇範觸築鹽襯範夢(鏇範網鏇鹽憲範齋憲淵) = 鑰餘觸積鏇鏇網淵衊餘 廠襯夢繭窪艱膚網糧窪 (艱衊襯餘願廠膚網鏇構, 0.21) 更多 | - | 2009-03-06 | ||
Placebo (Placebo Tablet) | 鏇顧鏇範觸築鹽襯範夢(鏇範網鏇鹽憲範齋憲淵) = 構廠簾遞膚願鑰窪繭鹽 廠襯夢繭窪艱膚網糧窪 (艱衊襯餘願廠膚網鏇構, 0.2) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用